Attached files
| file | filename |
|---|---|
| EX-10.77 - EX-10.77 - LUMOS PHARMA, INC. | a2204336zex-10_77.htm |
| EX-10.78 - EX-10.78 - LUMOS PHARMA, INC. | a2204336zex-10_78.htm |
| S-1/A - S-1/A - LUMOS PHARMA, INC. | a2201690zs-1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NewLink Genetics Corporation:
We consent to the use of our report dated February 25, 2011, except as to note 3, which is as of September 7, 2011, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
Our report refers to the adoption of new guidance on the presentation and disclosure of noncontrolling interests.
/s/ KPMG LLP
Des Moines, Iowa
September 13, 2011